- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Lexeo to help launch spinout around RNA drugs for the heart | 1 | BioPharma Dive | ||
| LEXEO THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Di | Lexeo Therapeutics, Perceptive Xontogeny Venture Funds and venBio Partners Announce Partnership to Advance Novel Cardiac RNA Therapeutics | 1 | GlobeNewswire (USA) | ||
| 13.06. | Lexeo Therapeutics files to sell 41.63M shares of common stock for holders | 1 | Seeking Alpha | ||
| 27.05. | Leerink senkt Kursziel für Lexeo Therapeutics auf 10 US-Dollar, behält Ausblick bei | 1 | Investing.com Deutsch | ||
| 27.05. | Leerink cuts Lexeo Therapeutics price target to $10, maintains outlook | 1 | Investing.com | ||
| 27.05. | Lexeo Therapeutics raises $80M in private placement | 2 | Seeking Alpha | ||
| 27.05. | Lexeo Therapeutics Announces $80 Mln Private Placement Of Shares | - | RTTNews | ||
| 27.05. | Lexeo Therapeutics secures $80 million in private placement | 1 | Investing.com | ||
| 27.05. | Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases | 2 | GlobeNewswire (USA) | ||
| 27.05. | Lexeo Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 16.05. | Lexeo stock price target cut to $15 by H.C. Wainwright | 1 | Investing.com | ||
| 12.05. | Lexeo laid off 15% of staff in April to focus on lead cardiac gene therapies | 1 | FierceBiotech | ||
| 12.05. | Lexeo Therapeutics, Inc. Q1 Loss Increases, Misses Estimates | - | RTTNews | ||
| 12.05. | Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights | 203 | GlobeNewswire (Europe) | Announced positive interim data for LX2006 from Phase 1/2 studies in Friederich ataxia (FA) cardiomyopathy; frataxin expression and LVMI improvement exceeded co-primary target thresholds for planned... ► Artikel lesen | |
| 12.05. | Lexeo Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.05. | Lexeo Therapeutics, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 01.05. | Lexeo Therapeutics to Present New CMC Data at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting | 3 | GlobeNewswire (USA) | ||
| 08.04. | H.C. Wainwright maintains Buy rating on Lexeo Therapeutics stock | 4 | Investing.com | ||
| 07.04. | Lexeo locks in pivotal trial plan as clinical data pump up prospects of cardiac gene therapy | 2 | FierceBiotech | ||
| 07.04. | Gene Therapy For Fatal Rare Disease-Associated Heart Condition - Lexeo Therapeutics Candidate Shows Improvements In Trials | 1 | Benzinga.com |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SANGAMO THERAPEUTICS | 0,469 | -3,60 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease | STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA)... ► Artikel lesen | |
| IMMUNITYBIO | 2,328 | -1,81 % | ImmunityBio, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| CYTOMX THERAPEUTICS | 2,076 | +4,48 % | CytomX Therapeutics Inc.: CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA (pembrolizumab) in Patients with Metastatic Melanoma | SOUTH SAN FRANCISCO, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that the... ► Artikel lesen | |
| ANAVEX LIFE SCIENCES | 8,300 | +4,48 % | Anavex Life Sciences Corp. Q2 Loss Beats Estimates | WASHINGTON (dpa-AFX) - Anavex Life Sciences Corp. (AVXL) released Loss for second quarter that beat the Street estimates.The company's earnings came in at -$11.20 million, or -$0.13 per share.... ► Artikel lesen | |
| ARDELYX | 3,174 | +0,79 % | Ardelyx, Inc.: Ardelyx Appoints Mike Kelliher Chief Business Officer and James P. Brady Chief Human Resources Officer | WALTHAM, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class... ► Artikel lesen | |
| CAPRICOR | 9,560 | +9,76 % | Capricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy | Four-year data show preservation of cardiac function, including LVEFSkeletal muscle disease progression continues to slow with extended treatment (PUL v2.0)Deramiocel's long-term safety profile remains... ► Artikel lesen | |
| AVID BIOSERVICES | 12,100 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 05.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 05.02.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 05.02.2025ISIN NameCA75525M1095 RAZOR... ► Artikel lesen | |
| AKEBIA | 3,112 | -2,51 % | Akebia Therapeutics, Inc.: Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of Nephrology | CAMBRIDGE, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease... ► Artikel lesen | |
| PROTALIX BIOTHERAPEUTICS | 1,230 | -2,38 % | Protalix BioTherapeutics, Inc. - 8-K, Current Report | ||
| KALVISTA PHARMACEUTICALS | 10,100 | +2,54 % | KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Enters into Licensing Agreement with Pendopharm to Commercialize Sebetralstat for HAE in Canada | -Sebetralstat has potential to become first oral on-demand treatment for HAE in Canada- -Pendopharm brings proven track record in commercializing innovative therapies across multiple therapeutic... ► Artikel lesen | |
| CORMEDIX | 10,900 | -14,84 % | CorMedix preist öffentliches Aktienangebot im Wert von 85 Millionen US-Dollar | ||
| ENZO BIOCHEM | 0,570 | +7,55 % | Enzo Biochem, Inc. To be Acquired by Battery Ventures in All-Cash Transaction | Transaction Follows Completion of Comprehensive Strategic Review by Special Committee of the Board to Maximize Shareholder Value Farmingdale, NY, June 24, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc.... ► Artikel lesen | |
| NUVATION BIO | 1,975 | +0,51 % | Nuvation Bio stock rating reiterated at Market Outperform by Citizens JMP | ||
| QUANTERIX | 6,560 | -0,15 % | Quanterix's Simoa analyzer gains medical device registration in S.Korea | ||
| IMMIX BIOPHARMA | 2,210 | -1,34 % | Immix Biopharma, Inc. - 8-K, Current Report |
LEXEO THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -0,48 % bei einem Aktienkurs von 4,160 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LEXEO THERAPEUTICS INC finden Sie auf Wallstreet Online.